Abstract 1: Phase III Multi-center Clinical Trial of Vitex negundo L. (Lagundi) Syrup vs. Placebo among Pediatric Patients with Cough of Moderate Severity (by Purificacion, Maramba et al.)

A total of 120 patients were screened but only 33 qualified for the study. There were 13 patients in the placebo group and 20 patients in the lagundi group with greater preponderance of males in the lagundi group. Patients’ age ranged from 6-16 yrs. The nutritional status was normal for both groups. Vital signs were within normal limits. Lagundi was evaluated for its effect on Peak Expiratory Flow Rate (PEFR) and Cough. The study revealed a 3% and 8.6% increase in PEFR on Day 4 and 8 in the placebo group, and a noticeable increase in PEFR of 14.6% and 12.3% in the lagundi treated group on Day 4 and 8. 12 out of 14 patients were free of cough in the lagundi treated group while only 3 out of 10 patients were cough free in the placebo group on Day 8. Global assessment as to response to therapy showed 84.6% and 80 % positive response for the placebo group on Day 4 and 8, whereas for the lagundi group, there was a 100% positive response both on Day 4 and 8. There were no adverse effects observed during the 8 days treatment with lagundi.


                                                                            [ Read More ]